New oral drug trial aims to save lives from dangerous transplant complication
NCT ID NCT07347990
Summary
This study is testing an oral medication called iptacopan for patients who develop a serious, high-risk blood clotting complication after a stem cell transplant. The trial will enroll 30 participants who have not responded to initial treatments. Researchers want to see if iptacopan improves survival at 6 months and helps patients recover blood counts and organ function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC MICROANGIOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China, 310003, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.